Innoviva, Inc. INVA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cost Reimbursement | $2.1M+250% | $2.7M— | $2.7M+800% | $1.4M+7.7% | $600K-53.8% | |
| Giapreza | $75.57M+23.4% | $73.61M+33.7% | $70.13M+34.7% | $65.45M+41.4% | $61.23M+38.0% | |
| Royalty | $233.84M-3.0% | $236.48M-2.2% | $244.1M-0.5% | $241.26M-0.3% | $241.13M+0.3% | |
| Xacduro | $84.68M+218% | $74.39M+253% | $49.04M+211% | $35.01M+432% | $26.62M— | |
| Royalty Expense by Product | ||||||
| Durlobactam | $0— | $0— | $0— | $0— | $0— | |
| Giapreza | $4.7M+27.0% | $4.5M+32.4% | $4.2M+34.4% | $4.1M+49.1% | $3.7M+38.3% | |
| Research And Development Expense by Product | ||||||
| External Services | $15.26M+73.2% | $15.71M+112% | $15.4M+58.6% | $14.96M+21.6% | $8.81M-47.2% | |
| Internal Expenses | $6.82M+27.2% | $5.53M-11.5% | $4.94M-43.6% | $4.63M-58.2% | $5.36M-57.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Innoviva, Inc. break its business down?
- Innoviva, Inc. (INVA) reports revenue by product across 4 parts — Cost Reimbursement, Giapreza, Royalty and Xacduro. Each is extracted from the segment footnotes and tracked over time.
- Where does Innoviva, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Innoviva, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
